Neuroinflammation, oxidative stress, and the pathogenesis of Parkinson's disease

Clinical Neuroscience Research

Volumn 6, Issue 5, 2006, Pages 261-281

  Lee Mosley, R ^a,b   Benner, Eric J ^a,b   Kadiu, Irena ^a,b   Thomas, Mark ^a,b   Boska, Michael D ^a,b,c   Hasan, Khader ^d   Laurie, Chad ^a,b   Gendelman, Howard E ^a,b  

^a NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^d UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Diffusion tensor imaging (DTI); Dopaminergic neurodegeneration; Dopaminergic neurons; Free radicals; Inflammation; Microglia; Oxidative stress; Parkinson's disease

Indexed keywords

ANTIOXIDANT; CD11B ANTIGEN; CD18 ANTIGEN; CD23 ANTIGEN; CD68 ANTIGEN; COMPLEMENT RECEPTOR; CYCLOOXYGENASE 2 INHIBITOR; FERRITIN; GAMMA INTERFERON; GLATIRAMER; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLUTAMIC ACID; HLA DR ANTIGEN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MATRIX METALLOPROTEINASE INHIBITOR; MINOCYCLINE; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; QUINOLINIC ACID; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SCAVENGER; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN EXPRESSION; ARTICLE; ASTROCYTE; AUTOCRINE EFFECT; BACTERICIDAL ACTIVITY; BLOOD BRAIN BARRIER; CELL ACTIVATION; CELL MIGRATION; CHEMOTAXIS; CLINICAL TRIAL; DEGENERATIVE DISEASE; DISEASE COURSE; DISEASE MODEL; ENDOTHELIUM CELL; EPIDEMIOLOGICAL DATA; GLIA CELL; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; INNATE IMMUNITY; LENTIVIRUS VECTOR; LIPID PEROXIDATION; MEDICAL RESEARCH; MICROGLIA; MISSENSE MUTATION; NERVE CELL LESION; NERVE CELL NECROSIS; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARACRINE SIGNALING; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN MODIFICATION; PROTEIN SYNTHESIS; STEADY STATE; TISSUE INJURY; UNSPECIFIED SIDE EFFECT; VIRAL GENE DELIVERY SYSTEM;

EID: 33845211714     PISSN: 15662772     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cnr.2006.09.006     Document Type: Article

References (264)

1. Mayeux R. Epidemiology of neurodegeneration. Annu Rev Neurosci 26 (2003) 81-104
2. Fahn S., and Przedborski S. Parkinsonism. In: Rowland L.P. (Ed). Merritt's neurology (2000), Lippincott Williams & Wilkins, New York 679-693
3. Fahn S., and Sulzer D. Neurodegeneration and neuroprotection in Parkinson disease. NeuroRx 1 (2004) 139-154
4. Hornykiewicz O., and Kish S.J. Biochemical pathophysiology of Parkinson's disease. Adv Neurol 45 (1987) 19-34
5. Clarke G., Collins R.A., Leavitt B.R., Andrews D.F., Hayden M.R., Lumsden C.J., et al. A one-hit model of cell death in inherited neuronal degenerations. Nature 406 (2000) 195-199
6. Orr C.F., Rowe D.B., and Halliday G.M. An inflammatory review of Parkinson's disease. Prog Neurobiol 68 (2002) 325-340
7. Dauer W., and Przedborski S. Parkinson's disease: mechanisms and models. Neuron 39 (2003) 889-909
8. Andersen J.K. Oxidative stress in neurodegeneration: cause or consequence? Nat Med 10 Suppl (2004) S18-S25
9. Przedborski S., Jackson-Lewis V., Vila M., Wu du C., Teismann P., Tieu K., et al. Free radical and nitric oxide toxicity in Parkinson's disease. Adv Neurol 91 (2003) 83-94
10. Dawson T.M., and Dawson V.L. Molecular pathways of neurodegeneration in Parkinson's disease. Science 302 (2003) 819-822
11. Vila M., and Przedborski S. Genetic clues to the pathogenesis of Parkinson's disease. Nat Med 10 Suppl (2004) S58-S62
12. Kreutzberg G.W. Microglia: a sensor for pathological events in the CNS. Trends Neurosci 19 (1996) 312-318
13. Schwartz M., Shaked I., Fisher J., Mizrahi T., and Schori H. Protective autoimmunity against the enemy within: fighting glutamate toxicity. Trends Neurosci 26 (2003) 297-302
14. Batchelor P.E., Porritt M.J., Martinello P., Parish C.L., Liberatore G.T., Donnan G.A., et al. Macrophages and microglia produce local trophic gradients that stimulate axonal sprouting toward but not beyond the wound edge. Mol Cell Neurosci 21 (2002) 436-453
15. Batchelor P.E., Liberatore G.T., Wong J.Y., Porritt M.J., Frerichs F., Donnan G.A., et al. Activated macrophages and microglia induce dopaminergic sprouting in the injured striatum and express brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor. J Neurosci 19 (1999) 1708-1716
16. McGeer P.L., and McGeer E.G. Innate immunity, local inflammation, and degenerative disease. Sci Aging Knowledge Environ 2002 (2002) re3
17. Banati R.B., Daniel S.E., and Blunt S.B. Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson's disease. Mov Disord 13 (1998) 221-227
18. Wahl L.M., Shankavaram U., and Zhang Y. Role of macrophages in vascular tissue remodelling. Transpl Immunol 5 (1997) 173-176
19. Takeda K., Kaisho T., and Akira S. Toll-like receptors. Annu Rev Immunol 21 (2003) 335-376
20. Wang P.Y., and Munford R.S. CD14-dependent internalization and metabolism of extracellular phosphatidylinositol by monocytes. J Biol Chem 274 (1999) 23235-23241
21. Callahan M.K., Halleck M.S., Krahling S., Henderson A.J., Williamson P., and Schlegel R.A. Phosphatidylserine expression and phagocytosis of apoptotic thymocytes during differentiation of monocytic cells. J Leukoc Biol 74 (2003) 846-856
22. Croisier E., Moran L.B., Dexter D.T., Pearce R.K., and Graeber M.B. Microglial inflammation in the parkinsonian substantia nigra: relationship to alpha-synuclein deposition. J Neuroinflammation 2 (2005) 14
23. Teismann P., Tieu K., Choi D.K., Wu D.C., Naini A., Hunot S., et al. Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc Natl Acad Sci USA 100 (2003) 5473-5478
24. Vila M., Jackson-Lewis V., Guegan C., Wu D.C., Teismann P., Choi D.K., et al. The role of glial cells in Parkinson's disease. Curr Opin Neurol 14 (2001) 483-489
25. Yamada T., McGeer P.L., and McGeer E.G. Lewy bodies in Parkinson's disease are recognized by antibodies to complement proteins. Acta Neuropathol (Berl) 84 (1992) 100-104
26. McGeer P.L., Itagaki S., Boyes B.E., and McGeer E.G. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 38 (1988) 1285-1291
27. Hunot S., and Hirsch E.C. Neuroinflammatory processes in Parkinson's disease. Ann Neurol 53 Suppl. 3 (2003) S49-S58 discussion S58-60
28. Mogi M., Harada M., Kondo T., Riederer P., and Nagatsu T. Brain beta 2-microglobulin levels are elevated in the striatum in Parkinson's disease. J Neural Transm Park Dis Dement Sect 9 (1995) 87-92
29. Nagatsu T., Mogi M., Ichinose H., and Togari A. Changes in cytokines and neurotrophins in Parkinson's disease. J Neural Transm Suppl (2000) 277-290
30. Boka G., Anglade P., Wallach D., Javoy-Agid F., Agid Y., and Hirsch E.C. Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease. Neurosci Lett 172 (1994) 151-154
31. Hunot S., Dugas N., Faucheux B., Hartmann A., Tardieu M., Debre P., et al. FcepsilonRII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells. J Neurosci 19 (1999) 3440-3447
32. McGeer P.L., Itagaki S., Akiyama H., and McGeer E.G. Rate of cell death in parkinsonism indicates active neuropathological process. Ann Neurol 24 (1988) 574-576
33. Mirza B., Hadberg H., Thomsen P., and Moos T. The absence of reactive astrocytosis is indicative of a unique inflammatory process in Parkinson's disease. Neuroscience 95 (2000) 425-432
34. Imamura K., Hishikawa N., Sawada M., Nagatsu T., Yoshida M., and Hashizume Y. Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains. Acta Neuropathol (Berl) 106 (2003) 518-526
35. Knott C., Stern G., and Wilkin G.P. Inflammatory regulators in Parkinson's disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2. Mol Cell Neurosci 16 (2000) 724-739
36. Lawson L.J., Perry V.H., Dri P., and Gordon S. Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience 39 (1990) 151-170
37. Chen H., Zhang S.M., Hernan M.A., Schwarzschild M.A., Willett W.C., Colditz G.A., et al. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol 60 (2003) 1059-1064
38. Hald A., and Lotharius J. Oxidative stress and inflammation in Parkinson's disease: is there a causal link?. Exp Neurol 193 (2005) 279-290
39. Wu D.C., Teismann P., Tieu K., Vila M., Jackson-Lewis V., Ischiropoulos H., et al. NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Proc Natl Acad Sci USA 100 (2003) 6145-6150
40. Babior B.M. NADPH oxidase: an update. Blood 93 (1999) 1464-1476
41. Hurley S.D., O'Banion M.K., Song D.D., Arana F.S., Olschowka J.A., and Haber S.N. Microglial response is poorly correlated with neurodegeneration following chronic, low-dose MPTP administration in monkeys. Exp Neurol 184 (2003) 659-668
42. Langston J.W., Ballard P., Tetrud J.W., and Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219 (1983) 979-980
43. Langston J.W., Forno L.S., Tetrud J., Reeves A.G., Kaplan J.A., and Karluk D. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol 46 (1999) 598-605
44. Babcock A.A., Kuziel W.A., Rivest S., and Owens T. Chemokine expression by glial cells directs leukocytes to sites of axonal injury in the CNS. J Neurosci 23 (2003) 7922-7930
45. Wyss-Coray T., and Mucke L. Inflammation in neurodegenerative disease-a double-edged sword. Neuron 35 (2002) 419-432
46. Huh G.S., Boulanger L.M., Du H., Riquelme P.A., Brotz T.M., and Shatz C.J. Functional requirement for class I MHC in CNS development and plasticity. Science 290 (2000) 2155-2159
47. Syken J., and Shatz C.J. Expression of T cell receptor beta locus in central nervous system neurons. Proc Natl Acad Sci USA 100 (2003) 13048-13053
48. Nishiyori A., Hanno Y., Saito M., and Yoshihara Y. Aberrant transcription of unrearranged T-cell receptor beta gene in mouse brain. J Comp Neurol 469 (2004) 214-226
49. Foster J.A., Quan N., Stern E.L., Kristensson K., and Herkenham M. Induced neuronal expression of class I major histocompatibility complex mRNA in acute and chronic inflammation models. J Neuroimmunol 131 (2002) 83-91
50. Cabarrocas J., Bauer J., Piaggio E., Liblau R., and Lassmann H. Effective and selective immune surveillance of the brain by MHC class I-restricted cytotoxic T lymphocytes. Eur J Immunol 33 (2003) 1174-1182
51. Schori H., Yoles E., Wheeler L.A., Raveh T., Kimchi A., and Schwartz M. Immune-related mechanisms participating in resistance and susceptibility to glutamate toxicity. Eur J Neurosci 16 (2002) 557-564
52. Kipnis J., Yoles E., Schori H., Hauben E., Shaked I., and Schwartz M. Neuronal survival after CNS insult is determined by a genetically encoded autoimmune response. J Neurosci 21 (2001) 4564-4571
53. Serpe C.J., Kohm A.P., Huppenbauer C.B., Sanders V.M., and Jones K.J. Exacerbation of facial motoneuron loss after facial nerve transection in severe combined immunodeficient (scid) mice. J Neurosci 19 (1999) 1-5
54. Stalder A.K., Carson M.J., Pagenstecher A., Asensio V.C., Kincaid C., Benedict M., et al. Late-onset chronic inflammatory encephalopathy in immune-competent and severe combined immune-deficient (SCID) mice with astrocyte-targeted expression of tumor necrosis factor. Am J Pathol 153 (1998) 767-783
55. Ransohoff R.M., Kivisakk P., and Kidd G. Three or more routes for leukocyte migration into the central nervous system. Nat Rev Immunol 3 (2003) 569-581
56. Aloisi F., Ambrosini E., Columba-Cabezas S., Magliozzi R., and Serafini B. Intracerebral regulation of immune responses. Ann Med 33 (2001) 510-515
57. Wekerle H., Linington C., Lassmann H., and Meyermann R. Cellular immune reactivity within the CNS. Trends Neurosci 9 (1986) 271-277
58. Bas J., Calopa M., Mestre M., Mollevi D.G., Cutillas B., Ambrosio S., et al. Lymphocyte populations in Parkinson's disease and in rat models of parkinsonism. J Neuroimmunol 113 (2001) 146-152
59. Hisanaga K., Asagi M., Itoyama Y., and Iwasaki Y. Increase in peripheral CD4 bright+ CD8 dull+ T cells in Parkinson disease. Arch Neurol 58 (2001) 1580-1583
60. Fiszer U., Mix E., Fredrikson S., Kostulas V., and Link H. Parkinson's disease and immunological abnormalities: increase of HLA-DR expression on monocytes in cerebrospinal fluid and of CD45RO+ T cells in peripheral blood. Acta Neurol Scand 90 (1994) 160-166
61. Bongioanni P., Castagna M., Maltinti S., Boccardi B., and Dadone F. T-lymphocyte tumor necrosis factor-alpha receptor binding in patients with Parkinson's disease. J Neurol Sci 149 (1997) 41-45
62. Bongioanni P., Mondino C., Borgna M., Boccardi B., Sposito R., and Castagna M. T-lymphocyte immuno-interferon binding in parkinsonian patients. J Neural Transm 104 (1997) 199-207
63. Bernabei P., Allione A., Rigamonti L., Bosticardo M., Losana G., Borghi I., et al. Regulation of interferon-gamma receptor (INF-gammaR) chains: a peculiar way to rule the life and death of human lymphocytes. Eur Cytokine Netw 12 (2001) 6-14
64. Cerutti P.A. Prooxidant states and tumor promotion. Science 227 (1985) 375-381
65. Petrozzi L., Lucetti C., Scarpato R., Gambaccini G., Trippi F., Bernardini S., et al. Cytogenetic alterations in lymphocytes of Alzheimer's disease and Parkinson's disease patients. Neurol Sci 23 Suppl. 2 (2002) S97-S98
66. Migliore L., Petrozzi L., Lucetti C., Gambaccini G., Bernardini S., Scarpato R., et al. Oxidative damage and cytogenetic analysis in leukocytes of Parkinson's disease patients. Neurology 58 (2002) 1809-1815
67. Mogi M., Harada M., Riederer P., Narabayashi H., Fujita K., and Nagatsu T. Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett 165 (1994) 208-210
68. Blum-Degen D., Muller T., Kuhn W., Gerlach M., Przuntek H., and Riederer P. Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci Lett 202 (1995) 17-20
69. Mogi M., Harada M., Kondo T., Riederer P., Inagaki H., Minami M., et al. Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci Lett 180 (1994) 147-150
70. Muller T., Blum-Degen D., Przuntek H., and Kuhn W. Interleukin-6 levels in cerebrospinal fluid inversely correlate to severity of Parkinson's disease. Acta Neurol Scand 98 (1998) 142-144
71. Araujo D.M., and Lapchak P.A. Induction of immune system mediators in the hippocampal formation in Alzheimer's and Parkinson's diseases: selective effects on specific interleukins and interleukin receptors. Neuroscience 61 (1994) 745-754
72. Hanisch U.K., and Quirion R. Interleukin-2 as a neuroregulatory cytokine. Brain Res Brain Res Rev 21 (1995) 246-284
73. Klegeris A., and McGeer P.L. Interaction of various intracellular signaling mechanisms involved in mononuclear phagocyte toxicity toward neuronal cells. J Leukoc Biol 67 (2000) 127-133
74. McGeer P.L., and McGeer E.G. Local neuroinflammation and the progression of Alzheimer's disease. J Neurovirol 8 (2002) 529-538
75. Blass J.P., and Gibson G.E. Cerebrometabolic aspects of delirium in relationship to dementia. Dement Geriatr Cogn Disord 10 (1999) 335-338
76. Lass A., Agarwal S., and Sohal R.S. Mitochondrial ubiquinone homologues, superoxide radical generation, and longevity in different mammalian species. J Biol Chem 272 (1997) 19199-19204
77. Chance B., Sies H., and Boveris A. Hydroperoxide metabolism in mammalian organs. Physiol Rev 59 (1979) 527-605
78. Singh R.P., Sharad S., and Kapur S. Free radicals and oxidative stress in neurodegenerative diseases: relevance of dietary antioxidants. J Indian Acad Clin Med 5 (2004) 218-225
79. Wallace D.C. Mitochondrial diseases in man and mouse. Science 283 (1999) 1482-1488
80. Vertuani S., Angusti A., and Manfredini S. The antioxidants and pro-antioxidants network: an overview. Curr Pharm Des 10 (2004) 1677-1694
81. Ischiropoulos H., and Beckman J.S. Oxidative stress and nitration in neurodegeneration: cause, effect, or association?. J Clin Invest 111 (2003) 163-169
82. Klebanoff S.J. Myeloperoxidase: friend and foe. J Leukoc Biol 77 (2005) 598-625
83. Mander P.K., Jekabsone A., and Brown G.C. Microglia proliferation is regulated by hydrogen peroxide from NADPH oxidase. J Immunol 176 (2006) 1046-1052
84. Locksley R.M., Wilson C.B., and Klebanoff S.J. Increased respiratory burst in myeloperoxidase-deficient monocytes. Blood 62 (1983) 902-909
85. Sankarapandi S., Zweier J.L., Mukherjee G., Quinn M.T., and Huso D.L. Measurement and characterization of superoxide generation in microglial cells: evidence for an NADPH oxidase-dependent pathway. Arch Biochem Biophys 353 (1998) 312-321
86. Sulzer D., and Zecca L. Intraneuronal dopamine-quinone synthesis: a review. Neurotox Res 1 (2000) 181-195
87. Graham D.G., Tiffany S.M., Bell Jr. W.R., and Gutknecht W.F. Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. Mol Pharmacol 14 (1978) 644-653
88. Graham D.G. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol 14 (1978) 633-643
89. Stokes A.H., Hastings T.G., and Vrana K.E. Cytotoxic and genotoxic potential of dopamine. J Neurosci Res 55 (1999) 659-665
90. Tse D.C., McCreery R.L., and Adams R.N. Potential oxidative pathways of brain catecholamines. J Med Chem 19 (1976) 37-40
91. MacMicking J.D., North R.J., LaCourse R., Mudgett J.S., Shah S.K., and Nathan C.F. Identification of nitric oxide synthase as a protective locus against tuberculosis. Proc Natl Acad Sci USA 94 (1997) 5243-5248
92. MacMicking J., Xie Q.W., and Nathan C. Nitric oxide and macrophage function. Annu Rev Immunol 15 (1997) 323-350
93. Dawson V.L., and Dawson T.M. Nitric oxide in neurodegeneration. Prog Brain Res 118 (1998) 215-229
94. Samdani A.F., Dawson T.M., and Dawson V.L. Nitric oxide synthase in models of focal ischemia. Stroke 28 (1997) 1283-1288
95. Brown G.C., and Bal-Price A. Inflammatory neurodegeneration mediated by nitric oxide, glutamate, and mitochondria. Mol. Neurobiol 27 (2003) 325-355
96. Liberatore G.T., Jackson-Lewis V., Vukosavic S., Mandir A.S., Vila M., McAuliffe W.G., et al. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat Med 5 (1999) 1403-1409
97. Przedborski S., Jackson-Lewis V., Yokoyama R., Shibata T., Dawson V.L., and Dawson T.M. Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. Proc Natl Acad Sci USA 93 (1996) 4565-4571
98. Chung K.K., Thomas B., Li X., Pletnikova O., Troncoso J.C., Marsh L., et al. S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function. Science 304 (2004) 1328-1331
99. Perry T.L., and Yong V.W. Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients. Neurosci Lett 67 (1986) 269-274
100. Sofic E., Lange K.W., Jellinger K., and Riederer P. Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci Lett 142 (1992) 128-130
101. Sian J., Dexter D.T., Lees A.J., Daniel S., Agid Y., Javoy-Agid F., et al. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 36 (1994) 348-355
102. Dringen R. Glutathione metabolism and oxidative stress in neurodegeneration. Eur J Biochem 267 (2000) 4903
103. Winterbourn C.C., and Metodiewa D. The reaction of superoxide with reduced glutathione. Arch Biochem Biophys 314 (1994) 284-290
104. Riederer P., Sofic E., Rausch W.D., Schmidt B., Reynolds G.P., Jellinger K., et al. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 52 (1989) 515-520
105. Jenner P. Altered mitochondrial function, iron metabolism and glutathione levels in Parkinson's disease. Acta Neurol Scand Suppl 146 (1993) 6-13
106. Pearce R.K., Owen A., Daniel S., Jenner P., and Marsden C.D. Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease. J Neural Transm 104 (1997) 661-677
107. Bharath S., Hsu M., Kaur D., Rajagopalan S., and Andersen J.K. Glutathione, iron and Parkinson's disease. Biochem Pharmacol 64 (2002) 1037-1048
108. Nakamura J., and Bannai S. Glutathione alters the mode of calcium-mediated regulation of adenylyl cyclase in membranes from mouse brain. Biochim Biophys Acta 1339 (1997) 239-246
109. Sian J., Dexter D.T., Lees A.J., Daniel S., Jenner P., and Marsden C.D. Glutathione-related enzymes in brain in Parkinson's disease. Ann Neurol 36 (1994) 356-361
110. Damier P., Hirsch E.C., Zhang P., Agid Y., and Javoy-Agid F. Glutathione peroxidase, glial cells and Parkinson's disease. Neuroscience 52 (1993) 1-6
111. Kang Y., Viswanath V., Jha N., Qiao X., Mo J.Q., and Andersen J.K. Brain gamma-glutamyl cysteine synthetase (GCS) mRNA expression patterns correlate with regional-specific enzyme activities and glutathione levels. J Neurosci Res 58 (1999) 436-441
112. Abbott L.C., Nejad H.H., Bottje W.G., and Hassan A.S. Glutathione levels in specific brain regions of genetically epileptic (tg/tg) mice. Brain Res Bull 25 (1990) 629-631
113. Chen T.S., Richie Jr. J.P., and Lang C.A. The effect of aging on glutathione and cysteine levels in different regions of the mouse brain. Proc Soc Exp Biol Med 190 (1989) 399-402
114. Spencer J.P., Jenner P., and Halliwell B. Superoxide-dependent depletion of reduced glutathione by L-DOPA and dopamine. Relevance to Parkinson's disease. Neuroreport 6 (1995) 1480-1484
115. Shen X.M., and Dryhurst G. Further insights into the influence of L-cysteine on the oxidation chemistry of dopamine: reaction pathways of potential relevance to Parkinson's disease. Chem Res Toxicol 9 (1996) 751-763
116. Spencer J.P., Jenner P., Daniel S.E., Lees A.J., Marsden D.C., and Halliwell B. Conjugates of catecholamines with cysteine and GSH in Parkinson's disease: possible mechanisms of formation involving reactive oxygen species. J Neurochem 71 (1998) 2112-2122
117. Chen Y., Vartiainen N.E., Ying W., Chan P.H., Koistinaho J., and Swanson R.A. Astrocytes protect neurons from nitric oxide toxicity by a glutathione-dependent mechanism. J Neurochem 77 (2001) 1601-1610
118. Ibi M., Sawada H., Kume T., Katsuki H., Kaneko S., Shimohama S., et al. Depletion of intracellular glutathione increases susceptibility to nitric oxide in mesencephalic dopaminergic neurons. J Neurochem 73 (1999) 1696-1703
119. Aoyama K., Matsubara K., Fujikawa Y., Nagahiro Y., Shimizu K., Umegae N., et al. Nitration of manganese superoxide dismutase in cerebrospinal fluids is a marker for peroxynitrite-mediated oxidative stress in neurodegenerative diseases. Ann Neurol 47 (2000) 524-527
120. Shergill J.K., Cammack R., Cooper C.E., Cooper J.M., Mann V.M., and Schapira A.H. Detection of nitrosyl complexes in human substantia nigra, in relation to Parkinson's disease. Biochem Biophys Res Commun 228 (1996) 298-305
121. Good P.F., Hsu A., Werner P., Perl D.P., and Olanow C.W. Protein nitration in Parkinson's disease. J Neuropathol Exp Neurol 57 (1998) 338-342
122. Giasson B.I., Duda J.E., Murray I.V., Chen Q., Souza J.M., Hurtig H.I., et al. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 290 (2000) 985-989
123. Duda J.E., Giasson B.I., Chen Q., Gur T.L., Hurtig H.I., Stern M.B., et al. Widespread nitration of pathological inclusions in neurodegenerative synucleinopathies. Am J Pathol 157 (2000) 1439-1445
124. Yao D., Gu Z., Nakamura T., Shi Z.Q., Ma Y., Gaston B., et al. Nitrosative stress linked to sporadic Parkinson's disease: S-nitrosylation of parkin regulates its E3 ubiquitin ligase activity. Proc Natl Acad Sci USA 101 (2004) 10810-10814
125. Floor E., and Wetzel M.G. Increased protein oxidation in human substantia nigra pars compacta in comparison with basal ganglia and prefrontal cortex measured with an improved dinitrophenylhydrazine assay. J Neurochem 70 (1998) 268-275
126. Alam Z.I., Daniel S.E., Lees A.J., Marsden D.C., Jenner P., and Halliwell B. A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease78. J Neurochem 69 (1997) 1326-1329
127. Schipper H.M., Liberman A., and Stopa E.G. Neural heme oxygenase-1 expression in idiopathic Parkinson's disease. Exp Neurol 150 (1998) 60-68
128. Castellani R., Smith M.A., Richey P.L., and Perry G. Glycoxidation and oxidative stress in Parkinson disease and diffuse Lewy body disease. Brain Res 737 (1996) 195-200
129. Loft S., and Poulsen H.E. Cancer risk and oxidative DNA damage in man. J Mol Med 74 (1996) 297-312
130. Sanchez-Ramos J.R., Overvik E., and Ames B.N. A marker of oxyradical-mediated DNA damage (8-hydroxy-2 '-deoxyguanosine) is increased in nigro-striatum of Parkinson's disease brain. Neurodegeneration 3 (1994) 197-204
131. Alam Z.I., Jenner A., Daniel S.E., Lees A.J., Cairns N., Marsden C.D., et al. Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J Neurochem 69 (1997) 1196-1203
132. Zhang J., Perry G., Smith M.A., Robertson D., Olson S.J., Graham D.G., et al. Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. Am J Pathol 154 (1999) 1423-1429
133. Shimura-Miura H., Hattori N., Kang D., Miyako K., Nakabeppu Y., and Mizuno Y. Increased 8-oxo-dGTPase in the mitochondria of substantia nigral neurons in Parkinson's disease. Ann Neurol 46 (1999) 920-924
134. Abe T., Isobe C., Murata T., Sato C., and Tohgi H. Alteration of 8-hydroxyguanosine concentrations in the cerebrospinal fluid and serum from patients with Parkinson's disease. Neurosci Lett 336 (2003) 105-108
135. Kikuchi A., Takeda A., Onodera H., Kimpara T., Hisanaga K., Sato N., et al. Systemic increase of oxidative nucleic acid damage in Parkinson's disease and multiple system atrophy. Neurobiol Dis 9 (2002) 244-248
136. Esterbauer H., Schaur R.J., and Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 11 (1991) 81-128
137. Uchida K., and Stadtman E.R. Modification of histidine residues in proteins by reaction with 4-hydroxynonenal. Proc Natl Acad Sci USA 89 (1992) 4544-4548
138. Yoritaka A., Hattori N., Uchida K., Tanaka M., Stadtman E.R., and Mizuno Y. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc Natl Acad Sci USA 93 (1996) 2696-2701
139. Castellani R.J., Perry G., Siedlak S.L., Nunomura A., Shimohama S., Zhang J., et al. Hydroxynonenal adducts indicate a role for lipid peroxidation in neocortical and brainstem Lewy bodies in humans. Neurosci Lett 319 (2002) 25-28
140. Zarkovic K. 4-hydroxynonenal and neurodegenerative diseases. Mol Aspects Med 24 (2003) 293-303
141. Okamoto K., Toyokuni S., Uchida K., Ogawa O., Takenewa J., Kakehi Y., et al. Formation of 8-hydroxy-2′-deoxyguanosine and 4-hydroxy-2-nonenal-modified proteins in human renal-cell carcinoma. Int J Cancer 58 (1994) 825-829
142. Toyokuni S., Uchida K., Okamoto K., Hattori-Nakakuki Y., Hiai H., and Stadtman E.R. Formation of 4-hydroxy-2-nonenal-modified proteins in the renal proximal tubules of rats treated with a renal carcinogen, ferric nitrilotriacetate. Proc Natl Acad Sci USA 91 (1994) 2616-2620
143. Picklo M.J., Amarnath V., McIntyre J.O., Graham D.G., and Montine T.J. 4-Hydroxy-2(E)-nonenal inhibits CNS mitochondrial respiration at multiple sites. J Neurochem 72 (1999) 1617-1624
144. Liu W., Kato M., Akhand A.A., Hayakawa A., Suzuki H., Miyata T., et al. 4-hydroxynonenal induces a cellular redox status-related activation of the caspase cascade for apoptotic cell death. J Cell Sci 113 (2000) 635-641
145. Camandola S., Poli G., and Mattson M.P. The lipid peroxidation product 4-hydroxy-2,3-nonenal inhibits constitutive and inducible activity of nuclear factor kappa B in neurons. Brain Res Mol Brain Res 85 (2000) 53-60
146. Okada K., Wangpoengtrakul C., Osawa T., Toyokuni S., Tanaka K., and Uchida K. 4-Hydroxy-2-nonenal-mediated impairment of intracellular proteolysis during oxidative stress. Identification of proteasomes as target molecules. J Biol Chem 274 (1999) 23787-23793
147. Hyun D.H., Lee M., Halliwell B., and Jenner P. Proteasomal inhibition causes the formation of protein aggregates containing a wide range of proteins, including nitrated proteins. J Neurochem 86 (2003) 363-373
148. Hyun D.H., Lee M.H., Halliwell B., and Jenner P. Proteasomal dysfunction induced by 4-hydroxy-2,3-trans-nonenal, an end-product of lipid peroxidation: a mechanism contributing to neurodegeneration?. J Neurochem 83 (2002) 360-370
149. Benzie I.F. Lipid peroxidation: a review of causes, consequences, measurement and dietary influences. Int J Food Sci Nutr 47 (1996) 233-261
150. Valenzuela A. The biological significance of malondialdehyde determination in the assessment of tissue oxidative stress. Life Sci 48 (1991) 301-309
151. Marnett L.J. Chemistry and biology of DNA damage by malondialdehyde. IARC Sci Publ (1999) 17-27
152. Bermejo P., Gomez-Serranillos P., Santos J., Pastor E., Gil P., and Martin-Aragon S. Determination of malonaldehyde in Alzheimer's disease: a comparative study of high-performance liquid chromatography and thiobarbituric acid test. Gerontology 43 (1997) 218-222
153. Dexter D.T., Carter C.J., Wells F.R., Javoy-Agid F., Agid Y., Lees A., et al. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 52 (1989) 381-389
154. Dexter D.T., Holley A.E., Flitter W.D., Slater T.F., Wells F.R., Daniel S.E., et al. Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: an HPLC and ESR study. Mov Disord 9 (1994) 92-97
155. Ilic T.V., Jovanovic M., Jovicic A., and Tomovic M. Oxidative stress indicators are elevated in de novo Parkinson's disease patients. Funct Neurol 14 (1999) 141-147
156. Fessel J.P., Hulette C., Powell S., Roberts II L.J., and Zhang J. Isofurans, but not F2-isoprostanes, are increased in the substantia nigra of patients with Parkinson's disease and with dementia with Lewy body disease. J Neurochem 85 (2003) 645-650
157. Montuschi P., Barnes P.J., and Roberts II L.J. Isoprostanes: markers and mediators of oxidative stress. FASEB J 18 (2004) 1791-1800
158. Roberts II L.J., Fessel J.P., and Davies S.S. The biochemistry of the isoprostane, neuroprostane, and isofuran Pathways of lipid peroxidation. Brain Pathol 15 (2005) 143-148
159. Pratico D., Lee V.M.-Y., Trojanowski J.Q., Rokach J., and Fitzgerald G.A. Increased F2-isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo. FASEB J 12 (1998) 1777-1783
160. Dexter D.T., Wells F.R., Agid F., Agid Y., Lees A.J., Jenner P., et al. Increased nigral iron content in postmortem parkinsonian brain. Lancet 2 (1987) 1219-1220
161. Sofic E., Riederer P., Heinsen H., Beckmann H., Reynolds G.P., Hebenstreit G., et al. Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J Neural Transm 74 (1988) 199-205
162. Dexter D.T., Wells F.R., Lees A.J., Agid F., Agid Y., Jenner P., et al. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem 52 (1989) 1830-1836
163. Hirsch E.C., Brandel J.P., Galle P., Javoy-Agid F., and Agid Y. Iron and aluminum increase in the substantia nigra of patients with Parkinson's disease: an X-ray microanalysis. J Neurochem 56 (1991) 446-451
164. Olanow C.W. Magnetic resonance imaging in parkinsonism. Neurol Clin 10 (1992) 405-420
165. Good P.F., Olanow C.W., and Perl D.P. Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: a LAMMA study. Brain Res 593 (1992) 343-346
166. Griffiths P.D., Dobson B.R., Jones G.R., and Clarke D.T. Iron in the basal ganglia in Parkinson's disease. An in vitro study using extended X-ray absorption fine structure and cryo-electron microscopy. Brain 122 (1999) 667-673
167. Loeffler D.A., Connor J.R., Juneau P.L., Snyder B.S., Kanaley L., DeMaggio A.J., et al. Transferrin and iron in normal, Alzheimer's disease, and Parkinson's disease brain regions. J Neurochem 65 (1995) 710-724
168. Griffiths P.D., and Crossman A.R. Distribution of iron in the basal ganglia and neocortex in postmortem tissue in Parkinson's disease and Alzheimer's disease. Dementia 4 (1993) 61-65
169. Sofic E., Paulus W., Jellinger K., Riederer P., and Youdim M.B. Selective increase of iron in substantia nigra zona compacta of parkinsonian brains. J Neurochem 56 (1991) 978-982
170. Mann V.M., Cooper J.M., Daniel S.E., Srai K., Jenner P., Marsden C.D., et al. Complex I, iron, and ferritin in Parkinson's disease substantia nigra. Ann Neurol 36 (1994) 876-881
171. Jellinger K., Paulus W., Grundke-Iqbal I., Riederer P., and Youdim M.B. Brain iron and ferritin in Parkinson's and Alzheimer's diseases. J Neural Transm Park Dis Dement Sect 2 (1990) 327-340
172. Zecca L., Youdim M.B., Riederer P., Connor J.R., and Crichton R.R. Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci 5 (2004) 863-873
173. Yoshida S., Ektessabi A., and Fujisawa S. XANES spectroscopy of a single neuron from a patient with Parkinson's disease. J Synchrotron Radiat 8 (2001) 998-1000
174. Halliwell B. Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment. Drugs Aging 18 (2001) 685-716
175. Kim S., Wing S.S., and Ponka P. S-Nitrosylation of IRP2 regulates its stability via the ubiquitin-proteasome pathway. Mol Cell Biol 24 (2004) 330-337
176. Smith S.R., Cooperman S., Lavaute T., Tresser N., Ghosh M., Meyron-Holtz E., et al. Severity of neurodegeneration correlates with compromise of iron metabolism in mice with iron regulatory protein deficiencies. Ann N Y Acad Sci 1012 (2004) 65-83
177. Li Y.J., Scott W.K., Hedges D.J., Zhang F., Gaskell P.C., Nance M.A., et al. Age at onset in two common neurodegenerative diseases is genetically controlled. Am J Hum Genet 70 (2002) 985-993
178. Li Y.J., Oliveira S.A., Xu P., Martin E.R., Stenger J.E., Scherzer C.R., et al. Glutathione S-transferase omega-1 modifies age-at-onset of Alzheimer disease and Parkinson disease. Hum Mol Genet 12 (2003) 3259-3267
179. Laliberte R.E., Perregaux D.G., Hoth L.R., Rosner P.J., Jordan C.K., Peese K.M., et al. Glutathione S-transferase omega 1-1 is a target of cytokine release inhibitory drugs and may be responsible for their effect on interleukin-1beta posttranslational processing. J Biol Chem 278 (2003) 16567-16578
180. Griffin W.S., and Mrak R.E. Interleukin-1 in the genesis and progression of and risk for development of neuronal degeneration in Alzheimer's disease. J Leukoc Biol 72 (2002) 233-238
181. Grimaldi L.M., Casadei V.M., Ferri C., Veglia F., Licastro F., Annoni G., et al. Association of early-onset Alzheimer's disease with an interleukin-1alpha gene polymorphism. Ann Neurol 47 (2000) 361-365
182. Noureddine M.A., Qin X.J., Oliveira S.A., Skelly T.J., van der Walt J., Hauser M.A., et al. Association between the neuron-specific RNA-binding protein ELAVL4 and Parkinson disease. Hum Genet 117 (2005) 27-33
183. Good P.J. A conserved family of elav-like genes in vertebrates. Proc Natl Acad Sci USA 92 (1995) 4557-4561
184. Nishimura M., Mizuta I., Mizuta E., Yamasaki S., Ohta M., and Kuno S. Influence of interleukin-1beta gene polymorphisms on age-at-onset of sporadic Parkinson's disease. Neurosci Lett 284 (2000) 73-76
185. Mizuta I., Nishimura M., Mizuta E., Yamasaki S., Ohta M., Kuno S., et al. Relation between the high production related allele of the interferon-gamma (IFN-gamma) gene and age at onset of idiopathic Parkinson's disease in Japan. J Neurol Neurosurg Psychiatry 71 (2001) 818-819
186. Giasson B.I., and Lee V.M. Are ubiquitination pathways central to Parkinson's disease?. Cell 114 (2003) 1-8
187. Singleton A.B., Farrer M., Johnson J., Singleton A., Hague S., Kachergus J., et al. alpha-Synuclein locus triplication causes Parkinson's disease. Science 302 (2003) 841
188. Masliah E., Rockenstein E., Veinbergs I., Mallory M., Hashimoto M., Takeda A., et al. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 287 (2000) 1265-1269
189. Auluck P.K., Chan H.Y., Trojanowski J.Q., Lee V.M., and Bonini N.M. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science 295 (2002) 865-868
190. Norris E.H., Giasson B.I., Ischiropoulos H., and Lee V.M. Effects of oxidative and nitrative challenges on alpha-synuclein fibrillogenesis involve distinct mechanisms of protein modifications. J Biol Chem 278 (2003) 27230-27240
191. Lindersson E., Beedholm R., Hojrup P., Moos T., Gai W., Hendil K.B., et al. Proteasomal inhibition by alpha-synuclein filaments and oligomers. J Biol Chem 279 (2004) 12924-12934
192. Petrucelli L., O'Farrell C., Lockhart P.J., Baptista M., Kehoe K., Vink L., et al. Parkin protects against the toxicity associated with mutant alpha-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons. Neuron 36 (2002) 1007-1019
193. Yang Y., Nishimura I., Imai Y., Takahashi R., and Lu B. Parkin suppresses dopaminergic neuron-selective neurotoxicity induced by Pael-R in Drosophila. Neuron 37 (2003) 911-924
194. Kitada T., Asakawa S., Hattori N., Matsumine H., Yamamura Y., Minoshima S., et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392 (1998) 605-608
195. Kurkowska-Jastrzebska I., Wronska A., Kohutnicka M., Czlonkowski A., and Czlonkowska A. MHC class II positive microglia and lymphocytic infiltration are present in the substantia nigra and striatum in mouse model of Parkinson's disease. Acta Neurobiol Exp (Wars) 59 (1999) 1-8
196. Kurkowska-Jastrzebska I., Wronska A., Kohutnicka M., Czlonkowski A., and Czlonkowska A. The inflammatory reaction following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxication in mouse. Exp Neurol 156 (1999) 50-61
197. He Y., Appel S., and Le W. Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum. Brain Res 909 (2001) 187-193
198. Gao H.M., Hong J.S., Zhang W., and Liu B. Distinct role for microglia in rotenone-induced degeneration of dopaminergic neurons. J Neurosci 22 (2002) 782-790
199. Sherer T.B., Betarbet R., Kim J.H., and Greenamyre J.T. Selective microglial activation in the rat rotenone model of Parkinson's disease. Neurosci Lett 341 (2003) 87-90
200. Gao H.M., Jiang J., Wilson B., Zhang W., Hong J.S., and Liu B. Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease. J Neurochem 81 (2002) 1285-1297
201. Kim W.G., Mohney R.P., Wilson B., Jeohn G.H., Liu B., and Hong J.S. Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia. J Neurosci 20 (2000) 6309-6316
202. Ryu J.K., Shin W.H., Kim J., Joe E.H., Lee Y.B., Cho K.G., et al. Trisialoganglioside GT1b induces in vivo degeneration of nigral dopaminergic neurons: role of microglia. Glia 38 (2002) 15-23
203. Przedborski S., Jackson-Lewis V., Djaldetti R., Liberatore G., Vila M., Vukosavic S., et al. The parkinsonian toxin MPTP: action and mechanism. Restor Neurol Neurosci 16 (2000) 135-142
204. Youdim M.B., Grunblatt E., Levites Y., Maor G., and Mandel S. Early and late molecular events in neurodegeneration and neuroprotection in Parkinson's disease MPTP model as assessed by cDNA microarray; the role of iron. Neurotox Res 4 (2002) 679-689
205. Teismann P., Tieu K., Cohen O., Choi D.K., Wu du C., Marks D., et al. Pathogenic role of glial cells in Parkinson's disease. Mov Disord 18 (2003) 121-129
206. Grunblatt E., Mandel S., and Youdim M.B. Neuroprotective strategies in Parkinson's disease using the models of 6-hydroxydopamine and MPTP. Ann N Y Acad Sci 899 (2000) 262-273
207. Lorenzl S., Calingasan N., Yang L., Albers D.S., Shugama S., Gregorio J., et al. Matrix metalloproteinase-9 is elevated in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice. Neuromolecular Med 5 (2004) 119-132
208. Shen Y.Q., Hebert G., Lin L.Y., Luo Y.L., Moze E., Li K.S., et al. Interleukine-1beta and interleukine-6 levels in striatum and other brain structures after MPTP treatment: influence of behavioral lateralization. J Neuroimmunol 158 (2005) 14-25
209. Akiyama H., and McGeer P.L. Microglial response to 6-hydroxydopamine-induced substantia nigra lesions. Brain Res 489 (1989) 247-253
210. Cicchetti F., Brownell A.L., Williams K., Chen Y.I., Livni E., and Isacson O. Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging. Eur J Neurosci 15 (2002) 991-998
211. Depino A.M., Earl C., Kaczmarczyk E., Ferrari C., Besedovsky H., del Rey A., et al. Microglial activation with atypical proinflammatory cytokine expression in a rat model of Parkinson's disease. Eur J Neurosci 18 (2003) 2731-2742
212. Betarbet R., Sherer T.B., MacKenzie G., Garcia-Osuna M., Panov A.V., and Greenamyre J.T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 3 (2000) 1301-1306
213. Fleming S.M., Zhu C., Fernagut P.O., Mehta A., DiCarlo C.D., Seaman R.L., et al. Behavioral and immunohistochemical effects of chronic intravenous and subcutaneous infusions of varying doses of rotenone. Exp Neurol 187 (2004) 418-429
214. Lapointe N., St-Hilaire M., Martinoli M.G., Blanchet J., Gould P., Rouillard C., et al. Rotenone induces non-specific central nervous system and systemic toxicity. Faseb J 18 (2004) 717-719
215. Brooks A.I., Chadwick C.A., Gelbard H.A., Cory-Slechta D.A., and Federoff H.J. Paraquat elicited neurobehavioral syndrome caused by dopaminergic neuron loss. Brain Res 823 (1999) 1-10
216. Thiruchelvam M., Richfield E.K., Baggs R.B., Tank A.W., and Cory-Slechta D.A. The nigrostriatal dopaminergic system as a preferential target of repeated exposures to combined paraquat and maneb: implications for Parkinson's disease. J Neurosci 20 (2000) 9207-9214
217. McCormack A.L., Thiruchelvam M., Manning-Bog A.B., Thiffault C., Langston J.W., Cory-Slechta D.A., et al. Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiol Dis 10 (2002) 119-127
218. Manning-Bog A.B., McCormack A.L., Purisai M.G., Bolin L.M., and Di Monte D.A. Alpha-synuclein overexpression protects against paraquat-induced neurodegeneration. J Neurosci 23 (2003) 3095-3099
219. McCormack A.L., Atienza J.G., Johnston L.C., Andersen J.K., Vu S., and Di Monte D.A. Role of oxidative stress in paraquat-induced dopaminergic cell degeneration. J Neurochem 93 (2005) 1030-1037
220. Liou H.H., Chen R.C., Tsai Y.F., Chen W.P., Chang Y.C., and Tsai M.C. Effects of paraquat on the substantia nigra of the wistar rats: neurochemical, histological, and behavioral studies. Toxicol Appl Pharmacol 137 (1996) 34-41
221. Wu X.F., Block M.L., Zhang W., Qin L., Wilson B., Zhang W.Q., et al. The role of microglia in paraquat-induced dopaminergic neurotoxicity. Antioxid Redox Signal 7 (2005) 654-661
222. Iravani M.M., Kashefi K., Mander P., Rose S., and Jenner P. Involvement of inducible nitric oxide synthase in inflammation-induced dopaminergic neurodegeneration. Neuroscience 110 (2002) 49-58
223. Liu B., Du L., and Hong J.S. Naloxone protects rat dopaminergic neurons against inflammatory damage through inhibition of microglia activation and superoxide generation. J Pharmacol Exp Ther 293 (2000) 607-617
224. Ling Z., Gayle D.A., Ma S.Y., Lipton J.W., Tong C.W., Hong J.S., et al. In utero bacterial endotoxin exposure causes loss of tyrosine hydroxylase neurons in the postnatal rat midbrain. Mov Disord 17 (2002) 116-124
225. Gayle D.A., Ling Z., Tong C., Landers T., Lipton J.W., and Carvey P.M. Lipopolysaccharide (LPS)-induced dopamine cell loss in culture: roles of tumor necrosis factor-alpha, interleukin-1beta, and nitric oxide. Brain Res Dev Brain Res 133 (2002) 27-35
226. Qin L., Liu Y., Wang T., Wei S.J., Block M.L., Wilson B., et al. NADPH oxidase mediates lipopolysaccharide-induced neurotoxicity and proinflammatory gene expression in activated microglia. J Biol Chem 279 (2004) 1415-1421
227. Block M.L., Wu X., Pei Z., Li G., Wang T., Qin L., et al. Nanometer size diesel exhaust particles are selectively toxic to dopaminergic neurons: the role of microglia, phagocytosis, and NADPH oxidase. FASEB J 18 (2004) 1618-1620
228. Dehmer T., Lindenau J., Haid S., Dichgans J., and Schulz J.B. Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo. J Neurochem 74 (2000) 2213-2216
229. Morale M.C., Serra P.A., Delogu M.R., Migheli R., Rocchitta G., Tirolo C., et al. Glucocorticoid receptor deficiency increases vulnerability of the nigrostriatal dopaminergic system: critical role of glial nitric oxide. FASEB J 18 (2004) 164-166
230. Yrjanheikki J., Tikka T., Keinanen R., Goldsteins G., Chan P.H., and Koistinaho J. A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc Natl Acad Sci USA 96 (1999) 13496-13500
231. Tikka T.M., and Koistinaho J.E. Minocycline provides neuroprotection against N-methyl-d-aspartate neurotoxicity by inhibiting microglia. J Immunol 166 (2001) 7527-7533
232. Tikka T., Fiebich B.L., Goldsteins G., Keinanen R., and Koistinaho J. Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. J Neurosci 21 (2001) 2580-2588
233. Wu D.C., Jackson-Lewis V., Vila M., Tieu K., Teismann P., Vadseth C., et al. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci 22 (2002) 1763-1771
234. Du Y., Ma Z., Lin S., Dodel R.C., Gao F., Bales K.R., et al. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc Natl Acad Sci USA 98 (2001) 14669-14674
235. Lin S., Zhang Y., Dodel R., Farlow M.R., Paul S.M., and Du Y. Minocycline blocks nitric oxide-induced neurotoxicity by inhibition p38 MAP kinase in rat cerebellar granule neurons. Neurosci Lett 315 (2001) 61-64
236. Sanchez Mejia R.O., Ona V.O., Li M., and Friedlander R.M. Minocycline reduces traumatic brain injury-mediated caspase-1 activation, tissue damage, and neurological dysfunction. Neurosurgery 48 (2001) 1393-1399
237. Teismann P., and Ferger B. Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease. Synapse 39 (2001) 167-174
238. Feng Z.H., Wang T.G., Li D.D., Fung P., Wilson B.C., Liu B., et al. Cyclooxygenase-2-deficient mice are resistant to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced damage of dopaminergic neurons in the substantia nigra. Neurosci Lett 329 (2002) 354-358
239. Feng Z., Li D., Fung P.C., Pei Z., Ramsden D.B., and Ho S.L. COX-2-deficient mice are less prone to MPTP-neurotoxicity than wild-type mice. Neuroreport 14 (2003) 1927-1929
240. Klivenyi P., Gardian G., Calingasan N.Y., Yang L., and Beal M.F. Additive neuroprotective effects of creatine and a cyclooxygenase 2 inhibitor against dopamine depletion in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease. J Mol Neurosci 21 (2003) 191-198
241. Hunot S., Vila M., Teismann P., Davis R.J., Hirsch E.C., Przedborski S., et al. JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease. Proc Natl Acad Sci USA 101 (2004) 665-670
242. Sanchez-Pernaute R., Ferree A., Cooper O., Yu M., Brownell A.L., and Isacson O. Selective COX-2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson's disease. J Neuroinflammation 1 (2004) 6
243. Carrasco E., Casper D., and Werner P. Dopaminergic neurotoxicity by 6-OHDA and MPP+: differential requirement for neuronal cyclooxygenase activity. J Neurosci Res 81 (2005) 121-131
244. Wang T., Pei Z., Zhang W., Liu B., Langenbach R., Lee C., et al. MPP+-induced COX-2 activation and subsequent dopaminergic neurodegeneration. FASEB J 19 (2005) 1134-1136
245. Lorenzl S., Albers D.S., Narr S., Chirichigno J., and Beal M.F. Expression of MMP-2, MMP-9, and MMP-1 and their endogenous counterregulators TIMP-1 and TIMP-2 in postmortem brain tissue of Parkinson's disease. Exp Neurol 178 (2002) 13-20
246. Gu Z., Kaul M., Yan B., Kridel S.J., Cui J., Strongin A., et al. S-Nitrosylation of matrix metalloproteinases: signaling pathway to neuronal cell death. Science 297 (2002) 1186-1190
247. Rachakonda V., Pan T.H., and Le W.D. Biomarkers of neurodegenerative disorders: how good are they?. Cell Res 14 (2004) 347-358
248. Hayley S., Crocker S.J., Smith P.D., Shree T., Jackson-Lewis V., Przedborski S., et al. Regulation of dopaminergic loss by Fas in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. J Neurosci 24 (2004) 2045-2053
249. Martin L.J. Neuronal cell death in nervous system development, disease, and injury (Review). Int J Mol Med 7 (2001) 455-478
250. Vila M., Jackson-Lewis V., Vukosavic S., Djaldetti R., Liberatore G., Offen D., et al. Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Proc Natl Acad Sci USA 98 (2001) 2837-2842
251. Kordower J.H., Emborg M.E., Bloch J., Ma S.Y., Chu Y., Leventhal L., et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 290 (2000) 767-773
252. Patel N.K., Bunnage M., Plaha P., Svendsen C.N., Heywood P., and Gill S.S. Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study. Ann Neurol 57 (2005) 298-302
253. Breidert T., Callebert J., Heneka M.T., Landreth G., Launay J.M., and Hirsch E.C. Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease. J Neurochem 82 (2002) 615-624
254. Angelov D.N., Waibel S., Guntinas-Lichius O., Lenzen M., Neiss W.F., Tomov T.L., et al. Therapeutic vaccine for acute and chronic motor neuron diseases: implications for amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 100 (2003) 4790-4795
255. Kipnis J., Mizrahi T., Hauben E., Shaked I., Shevach E., and Schwartz M. Neuroprotective autoimmunity: naturally occurring CD4+CD25+ regulatory T cells suppress the ability to withstand injury to the central nervous system. Proc Natl Acad Sci USA 99 (2002) 15620-15625
256. Bakalash S., Kipnis J., Yoles E., and Schwartz M. Resistance of retinal ganglion cells to an increase in intraocular pressure is immune-dependent. Invest Ophthalmol Vis Sci 43 (2002) 2648-2653
257. Kipnis J., Yoles E., Porat Z., Cohen A., Mor F., Sela M., et al. T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies. Proc Natl Acad Sci USA 97 (2000) 7446-7451
258. Arnon R., and Sela M. Immunomodulation by the copolymer glatiramer acetate. J Mol Recogn 16 (2003) 412-4121
259. Benner E.J., Mosley R.L., Destache C.J., Lewis T.B., Jackson-Lewis V., Gorantla S., et al. Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease. Proc Natl Acad Sci USA 101 (2004) 9435-9440
260. Boska M.D., Lewis T.B., Destache C.J., Benner E.J., Nelson J.A., Uberti M., et al. Quantitative 1H magnetic resonance spectroscopic imaging determines therapeutic immunization efficacy in an animal model of Parkinson's disease. J Neurosci 25 (2005) 1691-1700
261. Gao H.M., Liu B., Zhang W., and Hong J.S. Novel anti-inflammatory therapy for Parkinson's disease. Trends Pharmacol Sci 24 (2003) 395-401
262. Vitvitsky V, et al. J Biol Chem 2006, in press.
263. Gupta S, et al. J Biol Chem 2006, in press.
264. Thomas M et al, J Neurochem, 2006, in press.